Pharmaceutical - Oncology

Filter

Current filters:

Oncology

Popular Filters

1 to 25 of 1229 results

GSK and Novartis get European clearance for asset swap

GSK and Novartis get European clearance for asset swap

29-01-2015

UK pharma major GlaxoSmithKline has received clearance from the European Commission for its proposed…

EuropeFinancialGlaxoSmithKlineNovartisOncologyPharmaceuticalUK

Amgen and Onyx submit Kyprolis sNDA and marketing authorization application in USA and EU

Amgen and Onyx submit Kyprolis sNDA and marketing authorization application in USA and EU

28-01-2015

USA-based Amgen, the world’s leading independent biotech firm, and its subsidiary Onyx Pharmaceuticals…

AmgenKyprolisOncologyOnyx PharmaceuticalsPharmaceuticalRegulationUSA

Hybrigenics extends its partnership with Servier

27-01-2015

French biopharma company Hybrigenics says it has extended its partnership with France’s leading independent…

HybrigenicsOncologyPharmaceuticalResearchServier

Array acquires worldwide rights to encorafenib from Novartis

Array acquires worldwide rights to encorafenib from Novartis

23-01-2015

Oncology specialist Array Biopharma has reached an agreement with Swiss drug major Novartis to acquire…

Array BioPharmaencorafenibLicensingNovartisOncologyPharmaceutical

German Federal Joint Committee confirms 'considerable' benefit of Eisai's Halaven in breast cancer

German Federal Joint Committee confirms 'considerable' benefit of Eisai's Halaven in breast cancer

23-01-2015

The German Federal Joint Committee has confirmed the ‘considerable’ additional benefit of Japanese…

EisaiGermanyHalavenOncologyPharmaceuticalRegulation

Moderate growth forecast for colorectal cancer drug market

22-01-2015

The value of the colorectal cancer (CRC) therapeutics market will increase moderately, from $8.3 billion…

AvastinBayerBristol-Myers SquibbErbituxGlobalMarkets & MarketingMerck KGaAOncologyPharmaceuticalRocheStivarga

IQWiG reports negative views on Provenge, Velphoro and Zydelig

IQWiG reports negative views on Provenge, Velphoro and Zydelig

22-01-2015

The German Institute for Quality and Efficiency in Health Care (IQWiG) has reviewed a number of dossiers…

DendreonGermanyGilead SciencesNephrology and HepatologyOncologyPharmaceuticalPricingProvengeRegulationVelphoroVifor PharmaZydelig

Ariad gets positive final EC decision on Iclusig

20-01-2015

USA-based Ariad Pharmaceuticals today revealed that the European Commission has endorsed the final opinion…

Ariad PharmaceuticalsEuropeIclusigOncologyPharmaceuticalRegulation

Tiziana licenses potential cancer therapy milciclib from Nerviano

Tiziana licenses potential cancer therapy milciclib from Nerviano

20-01-2015

Oncology and immunology specialist Tiziana Life Sciences has exclusively licensed milciclib from Nerviano…

LicensingmilciclibNerviano Medical SciencesOncologyPharmaceuticalResearchTiziana

PharmaEngine says positive Phase III results achieved with pancreatic cancer candidate MM-398

20-01-2015

Taiwan's PharmaEngine says that the additional analyses from the global Phase III NAPOLI-1 study of MM-398…

Merrimack PharmaceuticalsMM-398OncologyPharmaceuticalPharmaEngineResearch

England's cancer outcomes worse than rest of Europe: National Audit Office report

England's cancer outcomes worse than rest of Europe: National Audit Office report

16-01-2015

The UK’s National Audit Office has published a report, Progress in improving cancer services and outcomes…

Markets & MarketingOncologyPharmaceuticalPoliticsPricingResearchUK

OncoGenex’ Ph III custirsen trial cleared to continue

16-01-2015

Canada’s OncoGenex Pharmaceuticals says that the AFFINITY trial is continuing as planned based upon…

custirsenOncoGenex PharmaceuticalsOncologyPharmaceuticalResearch

Boehringer opts to take up rights to Oxford BioThera’s oncology target

Boehringer opts to take up rights to Oxford BioThera’s oncology target

14-01-2015

Privately-held, UK-based Oxford BioTherapeutics says that German family-owned pharma major Boehringer…

Boehringer IngelheimLicensingOncologyOxford BioTherapeuticsPharmaceuticalUK

Boehringer Ingelheim enters research pact with Yale University

Boehringer Ingelheim enters research pact with Yale University

14-01-2015

German family-owned pharma major Boehringer Ingelheim has entered into a collaboration with Yale University,…

Boehringer IngelheimGermanyImmunologicalsOncologyPharmaceuticalResearchRespiratory and Pulmonary

Merck & Co updates on plans to accelerate new drug submissions and future growth

Merck & Co updates on plans to accelerate new drug submissions and future growth

13-01-2015

US pharma giant Merck & Co has reported on the ongoing execution of its multi-year, strategic initiative…

Anti-viralsgrazoprevir/elbasvirKeytrudaMerck & CoOncologyPharmaceuticalRegulationResearchUSA

NHS England raises budget for Cancer Drugs Fund but axes some products

NHS England raises budget for Cancer Drugs Fund but axes some products

13-01-2015

As has been widely expected and already much criticized, England’s over-stretched Cancer Drugs Fund…

FinancialHealthcareOncologyPharmaceuticalUK

Roche invests in Foundation Medicine collaboration

Roche invests in Foundation Medicine collaboration

12-01-2015

Swiss drug major Roche and Foundation Medicine have entered into a broad strategic collaboration.

EuropeFoundation MedicineLicensingOncologyPharmaceuticalRoche

Russia’s Nanolek commissions plant for production of nano-based drugs

12-01-2015

Russia's Nanolek has officially commissioned a new facility for the production of drugs for the treatment…

Antibiotics and Infectious diseasesCardio-vascularNanolekOncologyPharmaceuticalProductionRussia

Bristol-Myers stops Opdivo NSCLC study early on good results

12-01-2015

US pharma major Bristol-Myers Squibb says that an open-label, randomized Phase III study evaluating Opdivo…

Bristol-Myers SquibbOncologyOpdivoPharmaceuticalResearch

FDA sees no need for advisory panel meeting over Pfizer’s Ibrance

09-01-2015

US pharma giant Pfizer says it has been advised by the Food and Drug Administration that at this time…

IbranceOncologypalbociclibPfizerPharmaceuticalRegulationUSA

GW and Otsuka report Sativex failed to meet primary endpoint in cancer pain

GW and Otsuka report Sativex failed to meet primary endpoint in cancer pain

09-01-2015

UK-based GW Pharmaceuticals and Japanese drugmaker Otsuka have reported that Sativex (nabiximols) did…

AnalgesiaGW PharmaceuticalsOncologyOtsuka PharmaceuticalPharmaceuticalResearchSativexUKUSA

Kyowa Hakko Kirin to commercialize Syndax’ entinostat in Japan and Korea

Kyowa Hakko Kirin to commercialize Syndax’ entinostat in Japan and Korea

08-01-2015

Shares of Japanese mid-size drugmaker Kyowa Hakko Kirin rose 3.55% to 1,138 yen by afternoon trading…

Asia-PacificentinostatJapanKyowa Hakko KirinLicensingOncologyPharmaceuticalSyndax Pharmaceuticals

Drugmakers “outraged” at England's Cancer Drugs Fund decision to remove drugs from coverage

Drugmakers “outraged” at England's Cancer Drugs Fund decision to remove drugs from coverage

08-01-2015

England’s Cancer Drugs Fund is overspent and 42 drugs are being reassessed as price caps are brought…

AvastinEisaiHalavenHealthcareJevtanaKadcylaOncologyPharmaceuticalPricingRocheSanofiUKZaltrap

1 to 25 of 1229 results

Back to top